Incidences of dysesthesia occurred in 5.1%, 12.3%, and 12.5% of patients treated with retatrutide 4 mg, 9 mg, and 12 mg, respectively, compared with 0.9% with placebo, and incidences of urinary tract infections occurred in 7.5%, 8.8%, and 8.4% of patients treated with retatrutide 4 mg, 9 mg, and 12 mg, respectively, compared with 5.3% with placebo
Su vida media alcanza 13horas (LIRA) y 7das (SEMA), posibilitando la administracin subcutnea diaria y semanal, respectivamente, merced a las modificaciones estructurales indicadas5,10
Clayburgh, D
Resolution drops, making very small measurements harder to read accurately
Orlistat is the only oral medication currently licensed on the NHS for weight loss